In recent years, immune checkpoint inhibitors (ICIs), specifically anti-PD-1/PD-L1, have been applied for the treatment of metastatic urothelial carcinoma, and their role in bladder cancer is rapidly expanding. The gene discussed is CD274; the disease is urinary bladder carcinoma.